The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the other study I would uh reference is also a very small study that was done in 20 patients uh 10 of whom had um or 20 20 patients with Parkinson's disease 10 were put on nicotinamide riboside 10 on a placebo for four weeks and it saw some change in one of the movement disorder uh rating scales that's used to qu uh to subjectively uh quantify movement in patients with with PD
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The other study I would uh reference is also a very small study that was done in 20 patients uh 10 of whom had um or 20 20 patients with Parkinson's disease 10 were put on nicotinamide riboside 10 on a placebo for four weeks and it saw some change in one of the movement disorder uh rating scales that's used to qu uh to subjectively uh quantify movement in patients with with PD um but there was a bit of a catch because that was the the patients were also um there was a confounder in that some of those patients were closer in their last dose to levodopa which is a medication that in the early stages of the disease is quite effective at improving movement